Literature DB >> 35210825

Identification of a Nomogram with an Autophagy-Related Risk Signature for Survival Prediction in Patients with Glioma.

Xiaofeng Fu1, Luwei Hong2, Haiying Gong3, Guangjuan Kan4, Pengfei Zhang1, Ting-Ting Cui5, Gonglin Fan6, Xing Si7, Jiang Zhu1.   

Abstract

BACKGROUND: Glioma is a common type of tumor in the central nervous system characterized by high morbidity and mortality. Autophagy plays vital roles in the development and progression of glioma, and is involved in both normal physiological and various pathophysiological progresses. PATIENTS AND METHODS: A total of 531 autophagy-related genes (ARGs) were obtained and 1738 glioma patients were collected from three public databases. We performed least absolute shrinkage and selection operator regression to identify the optimal prognosis-related genes and constructed an autophagy-related risk signature. The performance of the signature was validated by receiver operating characteristic analysis, survival analysis, clinic correlation analysis, and Cox regression. A nomogram model was established by using multivariate Cox regression analysis. Schoenfeld's global and individual test were used to estimate time-varying covariance for the assumption of the Cox proportional hazard regression analysis. The R programming language was used as the main data analysis and visualizing tool.
RESULTS: An overall survival-related risk signature consisting of 15 ARGs was constructed and significantly stratified glioma patients into high- and low-risk groups (P < 0.0001). The area under the ROC curve of 1-, 3-, 5-year survival was 0.890, 0.923, and 0.889, respectively. Univariate and multivariate Cox analyses indicated that the risk signature was a satisfactory independent prognostic factor. Moreover, a nomogram model integrating risk signature with clinical information for predicting survival rates of patients with glioma was constructed (C-index=0.861±0.024).
CONCLUSION: This study constructed a novel and reliable ARG-related risk signature, which was verified as a satisfactory prognostic marker. The nomogram model could provide a reference for individually predicting the prognosis for each patient with glioma and promoting the selection of optimal treatment.
© 2022 Fu et al.

Entities:  

Keywords:  autophagy; glioma; nomogram; prognosis; risk signature

Year:  2022        PMID: 35210825      PMCID: PMC8857975          DOI: 10.2147/IJGM.S335571

Source DB:  PubMed          Journal:  Int J Gen Med        ISSN: 1178-7074


  52 in total

Review 1.  Annexin A5 as a potential marker in tumors.

Authors:  Boya Peng; Chunmei Guo; Hongwei Guan; Shuqing Liu; Ming-Zhong Sun
Journal:  Clin Chim Acta       Date:  2013-10-08       Impact factor: 3.786

Review 2.  TREM-1 and its potential ligands in non-infectious diseases: from biology to clinical perspectives.

Authors:  Alessandra Tammaro; Marc Derive; Sebastien Gibot; Jaklien C Leemans; Sandrine Florquin; Mark C Dessing
Journal:  Pharmacol Ther       Date:  2017-02-27       Impact factor: 12.310

Review 3.  Multidimensional communication in the microenvirons of glioblastoma.

Authors:  Marike L Broekman; Sybren L N Maas; Erik R Abels; Thorsten R Mempel; Anna M Krichevsky; Xandra O Breakefield
Journal:  Nat Rev Neurol       Date:  2018-08       Impact factor: 42.937

Review 4.  The dual roles of autophagy in gliomagenesis and clinical therapy strategies based on autophagic regulation mechanisms.

Authors:  Fan Feng; Moxuan Zhang; Chuanchao Yang; Xueyuan Heng; Xiujie Wu
Journal:  Biomed Pharmacother       Date:  2019-09-18       Impact factor: 6.529

5.  uPAR and cathepsin B inhibition enhanced radiation-induced apoptosis in gliomainitiating cells.

Authors:  Rama Rao Malla; Sreelatha Gopinath; Kiranmai Alapati; Bharathi Gorantla; Christopher S Gondi; Jasti S Rao
Journal:  Neuro Oncol       Date:  2012-05-09       Impact factor: 12.300

6.  A risk signature of three autophagy-related genes for predicting lower grade glioma survival is associated with tumor immune microenvironment.

Authors:  Jia-Zhe Lin; Nuan Lin
Journal:  Genomics       Date:  2020-10-15       Impact factor: 5.736

7.  Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors.

Authors:  Jeanette E Eckel-Passow; Daniel H Lachance; Annette M Molinaro; Kyle M Walsh; Paul A Decker; Hugues Sicotte; Melike Pekmezci; Terri Rice; Matt L Kosel; Ivan V Smirnov; Gobinda Sarkar; Alissa A Caron; Thomas M Kollmeyer; Corinne E Praska; Anisha R Chada; Chandralekha Halder; Helen M Hansen; Lucie S McCoy; Paige M Bracci; Roxanne Marshall; Shichun Zheng; Gerald F Reis; Alexander R Pico; Brian P O'Neill; Jan C Buckner; Caterina Giannini; Jason T Huse; Arie Perry; Tarik Tihan; Mitchell S Berger; Susan M Chang; Michael D Prados; Joseph Wiemels; John K Wiencke; Margaret R Wrensch; Robert B Jenkins
Journal:  N Engl J Med       Date:  2015-06-10       Impact factor: 176.079

8.  Distinct subgroup of the Ras family member 3 (DIRAS3) expression impairs metastasis and induces autophagy of gastric cancer cells in mice.

Authors:  Jingping Qiu; Xiaoting Li; Yingjian He; Dan Sun; Wenhui Li; Yan Xin
Journal:  J Cancer Res Clin Oncol       Date:  2018-07-24       Impact factor: 4.553

9.  Development and Validation of an IDH1-Associated Immune Prognostic Signature for Diffuse Lower-Grade Glioma.

Authors:  Xiangyang Deng; Dongdong Lin; Bo Chen; Xiaojia Zhang; Xingxing Xu; Zelin Yang; Xuchao Shen; Liang Yang; Xiangqi Lu; Hansong Sheng; Bo Yin; Nu Zhang; Jian Lin
Journal:  Front Oncol       Date:  2019-11-22       Impact factor: 6.244

10.  Identification and validation of an autophagy-related signature for predicting survival in lower-grade glioma.

Authors:  Shaobin Feng; Huiling Liu; Xushuai Dong; Peng Du; Hua Guo; Qi Pang
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

View more
  1 in total

Review 1.  Protein Quality Control in Glioblastoma: A Review of the Current Literature with New Perspectives on Therapeutic Targets.

Authors:  Angela Rocchi; Hassen S Wollebo; Kamel Khalili
Journal:  Int J Mol Sci       Date:  2022-08-27       Impact factor: 6.208

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.